Synmosa Biopharma Corporation (4114.TWO)
- Previous Close
34.20 - Open
34.25 - Bid 34.10 x --
- Ask 34.15 x --
- Day's Range
33.65 - 34.45 - 52 Week Range
28.90 - 38.35 - Volume
590,175 - Avg. Volume
1,359,691 - Market Cap (intraday)
15.548B - Beta (5Y Monthly) --
- PE Ratio (TTM)
20.54 - EPS (TTM)
1.66 - Earnings Date --
- Forward Dividend & Yield 0.60 (1.74%)
- Ex-Dividend Date Aug 9, 2024
- 1y Target Est
--
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, sex hormones, and other forms. In addition, it offers contract manufacturing services. The company also exports its products to South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, and other countries. Synmosa Biopharma Corporation was incorporated in 1980 and is headquartered in Taipei, Taiwan.
www.synmosa.com.tw--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 4114.TWO
View MorePerformance Overview: 4114.TWO
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4114.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4114.TWO
View MoreValuation Measures
Market Cap
15.59B
Enterprise Value
15.12B
Trailing P/E
20.59
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.56
Price/Book (mrq)
1.90
Enterprise Value/Revenue
2.65
Enterprise Value/EBITDA
14.18
Financial Highlights
Profitability and Income Statement
Profit Margin
12.42%
Return on Assets (ttm)
3.76%
Return on Equity (ttm)
5.55%
Revenue (ttm)
5.72B
Net Income Avi to Common (ttm)
710.08M
Diluted EPS (ttm)
1.66
Balance Sheet and Cash Flow
Total Cash (mrq)
3.13B
Total Debt/Equity (mrq)
27.73%
Levered Free Cash Flow (ttm)
589.96M